# Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

> **NCT02145611** · PHASE4 · COMPLETED · sponsor: **Dr. José Fernando Vilela-Martin MD PhD** · enrollment: 50 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Hypertension
- Endothelial Dysfunction

## Interventions

- **DRUG:** Glibenclamide
- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT02145611
- **Lead sponsor:** Dr. José Fernando Vilela-Martin MD PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145611, "Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02145611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*